INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME: A Double-blind Controlled Trial

INTERMITTENT EPOPROSTENOL (PROSTACYCLIN) INFUSION IN PATIENTS WITH RAYNAUD'S SYNDROME: A Double-blind Controlled Trial

Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7·5 ng/kg/min after the first...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet (British edition) 1983-02, Vol.321 (8320), p.313-315
Hauptverfasser: Belch, JillJ.F., Drury, JohnK, Capell, Hilary, Forbes, CharlesD, Newman, Peter, Mckenzie, Fiona, Leiberman, Paul, Prentice, ColinR.M.
Format: Artikel
Sprache:eng
Schlagworte:
Buffers
Intravenous administration
Intravenous infusion
Prostacyclin
Raynaud disease
Temperature measurement
Thermocouples
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Two groups of outpatients (7 in each group) with Raynaud's syndrome, matched for severity of illness, were randomly allocated to receive at weekly intervals for three weeks either a 5 h intravenous infusion of buffer or epoprostenol (prostacyclin, PGI2) in buffer (7·5 ng/kg/min after the first hour). PGI2 reduced the frequency and duration of ischaemic attacks (both p
ISSN:0140-6736
1474-547X
DOI:10.1016/S0140-6736(83)91624-0